-+ 0.00%
-+ 0.00%
-+ 0.00%

Inhibikase Therapeutics Q2 EPS $(0.11), Inline

Benzinga·08/11/2026 20:16:16
Listen to the news
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.